Historic Progress for Endometrial Cancer Research—Now Let’s Finish the Job

For the first time, $10 million for a dedicated Department of Defense (DoD) endometrial cancer research program has been authorized in the National Defense Appropriations Act (NDAA). This is more than incremental progress—it is a clear signal that endometrial cancer is gaining long-overdue national attention.

As one of the only cancers with both rising incidence and mortality, endometrial cancer demands focused investment. This milestone reflects growing recognition among policymakers that advancing research in this space is both urgent and necessary.

A Major Milestone Years in the Making

The newly authorized program will be housed within the DoD’s Congressionally Directed Medical Research Programs (CDMRP), a highly competitive, peer-reviewed funding mechanism known for supporting innovative, high-impact science. Inclusion in CDMRP marks a significant step forward for the gynecologic oncology community.

This achievement builds on more than a decade of sustained advocacy led by the Society of Gynecologic Oncology (SGO), in partnership with patient advocates and dedicated congressional champions, including Representative Bonnie Watson Coleman (D-NJ) and Representative Bill Keating (D-MA).

Authorization Is Just the Beginning

While authorization in the NDAA is a critical breakthrough, it does not guarantee funding. Congress must still include the $10 million appropriation in the Fiscal Year (FY) 2027 Department of Defense spending bill for researchers to access these funds.

In other words, we are closer than ever—but not across the finish line.

Why Action Is Needed Now

Congress is actively shaping its FY 2027 funding priorities, with key decisions happening in the coming weeks. This is a pivotal moment where strong engagement from the SGO community and advocates nationwide can make the difference.

Broad, timely outreach helps demonstrate to lawmakers that this funding is not only warranted—but expected.

Your Voice Matters

SGO members, advocates, and supporters have a critical role to play in securing this funding.

Take a moment to contact your Representative using a pre-populated message urging support for the $10 million appropriation. It takes just seconds to send, but the impact is significant. Urge your representative to sign by March 19, 2026.

You can also help amplify this effort by sharing the message with colleagues, patients, and your broader network. Every voice adds momentum.

Looking Ahead

This authorization represents a historic step forward for endometrial cancer research. With one final push, we can ensure this program becomes a funded reality—accelerating discoveries and improving outcomes for patients.

Now is the time to act.